Cargando…

Local recurrence management of extremity soft tissue sarcoma

Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Serban, Bogdan, Cretu, Bogdan, Cursaru, Adrian, Nitipir, Cornelia, Orlov-Slavu, Cristina, Cirstoiu, Catalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441250/
https://www.ncbi.nlm.nih.gov/pubmed/37526250
http://dx.doi.org/10.1530/EOR-23-0095
_version_ 1785093343016910848
author Serban, Bogdan
Cretu, Bogdan
Cursaru, Adrian
Nitipir, Cornelia
Orlov-Slavu, Cristina
Cirstoiu, Catalin
author_facet Serban, Bogdan
Cretu, Bogdan
Cursaru, Adrian
Nitipir, Cornelia
Orlov-Slavu, Cristina
Cirstoiu, Catalin
author_sort Serban, Bogdan
collection PubMed
description Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years. The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity. Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease’s recurrence. The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach.
format Online
Article
Text
id pubmed-10441250
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-104412502023-08-22 Local recurrence management of extremity soft tissue sarcoma Serban, Bogdan Cretu, Bogdan Cursaru, Adrian Nitipir, Cornelia Orlov-Slavu, Cristina Cirstoiu, Catalin EFORT Open Rev Oncology Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years. The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity. Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease’s recurrence. The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach. Bioscientifica Ltd 2023-08-01 /pmc/articles/PMC10441250/ /pubmed/37526250 http://dx.doi.org/10.1530/EOR-23-0095 Text en © the author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Oncology
Serban, Bogdan
Cretu, Bogdan
Cursaru, Adrian
Nitipir, Cornelia
Orlov-Slavu, Cristina
Cirstoiu, Catalin
Local recurrence management of extremity soft tissue sarcoma
title Local recurrence management of extremity soft tissue sarcoma
title_full Local recurrence management of extremity soft tissue sarcoma
title_fullStr Local recurrence management of extremity soft tissue sarcoma
title_full_unstemmed Local recurrence management of extremity soft tissue sarcoma
title_short Local recurrence management of extremity soft tissue sarcoma
title_sort local recurrence management of extremity soft tissue sarcoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441250/
https://www.ncbi.nlm.nih.gov/pubmed/37526250
http://dx.doi.org/10.1530/EOR-23-0095
work_keys_str_mv AT serbanbogdan localrecurrencemanagementofextremitysofttissuesarcoma
AT cretubogdan localrecurrencemanagementofextremitysofttissuesarcoma
AT cursaruadrian localrecurrencemanagementofextremitysofttissuesarcoma
AT nitipircornelia localrecurrencemanagementofextremitysofttissuesarcoma
AT orlovslavucristina localrecurrencemanagementofextremitysofttissuesarcoma
AT cirstoiucatalin localrecurrencemanagementofextremitysofttissuesarcoma